
Eisai’s Kisplyx (lenvatinib) has secured recommendation from the Scottish Medicines Consortium, it has been revealed, meaning that patients on the …

The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care

